Business Context and Reporting Period
This Form 8-K Current Report was filed by Brooks Automation, Inc. on November 15, 2018. The filing discloses the completion of a major acquisition and the entry into a material definitive financing agreement to support the transaction. Note: The request metadata referenced "Azenta, Inc.," but the filing text explicitly identifies the registrant as Brooks Automation, Inc.
Key Financial Metrics and Transaction Details
- Acquisition Price: Total cash purchase price of $450.0 million for Genewiz Group, subject to closing adjustments for cash, working capital, and indebtedness.
- Financing: Entered into an Incremental Amendment to its Credit Agreement to secure a senior secured term loan facility of $350.0 million.
- Interest Rates: Borrowings bear interest at either (a) ABR plus 1.50% or (b) Adjusted LIBO Rate plus 2.50%.
- Use of Proceeds: The $350 million Incremental Loan proceeds were used to finance a portion of the Genewiz acquisition.
- Debt Structure: The new Incremental Loan is secured on a pari passu basis with existing Initial Term B Loans.
Material Changes
The primary material change is the expansion of the Company's operations through the acquisition of Genewiz, a leading global genomics service provider headquartered in South Plainfield, New Jersey. Concurrently, the Company's debt obligations increased by $350 million via the new term loan facility.
Outlook, Risks, and Contingencies
- Future Filings: The Company will file financial statements of the acquired business and pro forma financial information within 71 calendar days of this report.
- Adjustments: The final purchase price is contingent on adjustments related to Genewiz's net working capital, accounts receivable (subject to a collar), and transaction expenses.
- Reference Documents: Full terms are subject to the Merger Agreement (Exhibit 2.1) and the Incremental Amendment (Exhibit 10.1).
Investor Verification Checklist
- Verify the final adjusted purchase price for Genewiz once closing adjustments are finalized.
- Review the upcoming pro forma financial information to assess the impact of the $350 million debt load on leverage ratios.
- Confirm the integration timeline and strategic rationale for entering the genomics service sector.
- Examine the full text of the Incremental Amendment (Exhibit 10.1) for specific covenants and prepayment terms.